These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 36267193)

  • 1. Severe Bradycardia Leading to Hemodynamic Instability Associated with Remdesivir Use in a Patient with COVID-19 Pneumonia.
    Donepudi B; Agarwal S; Thakur L
    Case Rep Crit Care; 2022; 2022():8807957. PubMed ID: 36267193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bradyarrhythmia After Remdesivir Administration in SARS-CoV-2: A Review of Literature and Meta-Analysis of Observational Studies in Epidemiology.
    Al-Jammali S; Al-Zakhari R; Sheets N; Mahtani A; Stefanishina V; Isber N
    Cardiol Res; 2022 Jun; 13(3):135-143. PubMed ID: 35836734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism.
    Filtz A; Carandina A; Fasiello A; Barbetta L; Lombardi R; Cinque F; Rizzi G; Ceriani E; Furlan L; Bellocchi C; Fracanzani AL; Hu C; Cogliati C; Canetta C; Peyvandi F; Montano N; Tobaldini E
    Intern Emerg Med; 2023 Mar; 18(2):359-366. PubMed ID: 36539604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series.
    Lee C; Ahn MY; Byeon K; Choi JP; Hahm C; Kim H; Kim S; Kim TH; Oh J; Oh DH
    Infect Chemother; 2020 Sep; 52(3):369-380. PubMed ID: 32757500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19.
    Li J; Zhang K; Wu D; Ren L; Chu X; Qin C; Han X; Hang T; Xu Y; Yang L; Yin L
    Asian J Pharm Sci; 2021 Nov; 16(6):772-783. PubMed ID: 34703490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Remdesivir in Hospitalized Pediatric COVID-19: A Retrospective Case-Controlled Study.
    Khalil A; Mohamed A; Hassan M; Magboul S; Ali H; Elmasoudi AS; Ellithy K; Qusad M; Alhothi A; Al Maslamani E; Al Amri M; Soliman A
    Ther Clin Risk Manag; 2023; 19():949-958. PubMed ID: 38023628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse effects of remdesivir for the treatment of acute COVID-19 in the pediatric population: a retrospective observational study.
    Schulz A; Huynh N; Heger M; Bakir M
    Mol Cell Pediatr; 2024 Feb; 11(1):2. PubMed ID: 38381231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remdesivir-Induced Extreme Sinus Bradycardia in COVID-19.
    Wasef N; Hamilton S; Fatima T; Osgood E
    Cureus; 2022 Jul; 14(7):e27307. PubMed ID: 35910702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.
    Pruijssers AJ; George AS; Schäfer A; Leist SR; Gralinksi LE; Dinnon KH; Yount BL; Agostini ML; Stevens LJ; Chappell JD; Lu X; Hughes TM; Gully K; Martinez DR; Brown AJ; Graham RL; Perry JK; Du Pont V; Pitts J; Ma B; Babusis D; Murakami E; Feng JY; Bilello JP; Porter DP; Cihlar T; Baric RS; Denison MR; Sheahan TP
    Cell Rep; 2020 Jul; 32(3):107940. PubMed ID: 32668216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remdesivir therapy causing bradycardia in COVID-19 patients: Two case reports.
    Abdelmajid A; Osman W; Musa H; Elhiday H; Munir W; Al Maslamani MA; Elmekaty EZ
    IDCases; 2021; 26():e01254. PubMed ID: 34401329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action.
    Tchesnokov EP; Gordon CJ; Woolner E; Kocinkova D; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 Nov; 295(47):16156-16165. PubMed ID: 32967965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Remdesivir on mortality and length of stay in hospitalized COVID-19 patients: A single center study.
    Shaikh Q; Sarfaraz S; Rahim A; Hussain M; Shah R; Soomro S
    Pak J Med Sci; 2022 Jan; 38(2):405-410. PubMed ID: 35310809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.
    Pruijssers AJ; George AS; Schäfer A; Leist SR; Gralinksi LE; Dinnon KH; Yount BL; Agostini ML; Stevens LJ; Chappell JD; Lu X; Hughes TM; Gully K; Martinez DR; Brown AJ; Graham RL; Perry JK; Du Pont V; Pitts J; Ma B; Babusis D; Murakami E; Feng JY; Bilello JP; Porter DP; Cihlar T; Baric RS; Denison MR; Sheahan TP
    bioRxiv; 2020 Apr; ():. PubMed ID: 32511392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.
    Gordon CJ; Tchesnokov EP; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 Apr; 295(15):4773-4779. PubMed ID: 32094225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiological and sick sinus syndrome effects of Remdesivir challenge in guinea-pig hearts.
    Li S; Yue L; Xie Y; Zhang H
    Front Physiol; 2024; 15():1436727. PubMed ID: 39193439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent?
    Maheshwari M; Athiraman H
    Cureus; 2021 Nov; 13(11):e19919. PubMed ID: 34956798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review.
    Barkas F; Styla CP; Bechlioulis A; Milionis H; Liberopoulos E
    J Cardiovasc Dev Dis; 2021 Feb; 8(2):. PubMed ID: 33673216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir.
    Gordon CJ; Lee HW; Tchesnokov EP; Perry JK; Feng JY; Bilello JP; Porter DP; Götte M
    J Biol Chem; 2022 Feb; 298(2):101529. PubMed ID: 34953856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period.
    Elshaboury RH; Monk MM; Bebell LM; Bidell MR; Adamsick ML; Gandhi RG; Paras ML; Hohmann EL; Letourneau AR
    Ther Adv Infect Dis; 2021; 8():20499361211046669. PubMed ID: 34589214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.